ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Cyclophosphamide

Also written as “cyclophosphamide”, “Cyclophosphamide,Fludarabine” and “Cytoxan”.

Its studies are mostly in Breast Neoplasms · Multiple Myeloma · Lymphoma, Large B-Cell, Diffuse · Leukemia, Lymphocytic, Chronic, B-Cell · Carcinoma, Non-Small-Cell Lung, led by 28 companies.

Drug pageCyclophosphamide: every studyMany companies study it; this page follows only the 70 they lead. All 1,538 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jan 4, 201170 company-led studies, 25 open or runningNext primary completion: Jan 14, 2027 (early phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Rocheits history only151 open or runningphase 4since Jan 4, 2011Oct 16, 2007Feb 28, 2028phase 2 · NCT04931342
Beijing Biotechits history only99 open or runningphase 2since Apr 5, 2026Mar 14, 2026Feb 18, 2027phase 1 · NCT07480941
ImmunoVaccine Technologies, Inc. (IMV Inc.)its history only63 open or runningphase 2since Dec 12, 2014Dec 12, 2014none ahead
Amgenits history only40 open or runningphase 2since Jul 5, 2000Jul 5, 2000none ahead
Sanofiits history only40 open or runningphase 3since Jul 11, 2001Jul 11, 2001none ahead
Takedaits history only41 open or runningphase 2since Jul 25, 2007Jul 25, 2007none ahead
Allogene Therapeuticsits history only32 open or runningphase 2since Dec 8, 2022Dec 8, 2022Dec 2027phase 2 · NCT06500273
Bristol-Myers Squibbits history only21 open or runningphase 2since Dec 22, 2016Dec 22, 2016Mar 15, 2029phase 1 · NCT07115745
Hangzhou Huasai Biomedicineits history only22 open or runningphase 1since Jul 22, 2025Jul 22, 2025Aug 30, 2027phase 1 · NCT07105176
Rampart Healthits history only21 open or runningphase 2since Aug 9, 2019Aug 9, 2019none ahead
Gilead Sciences10 open or runningphase 1since Oct 13, 2017Oct 13, 2017none ahead

Also a collaborator on its studies: Natera, Incyte, AbbVie and Johnson & Johnson.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Gilead Sciences only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 13, 2017First study: phase 1 study in Multiple MyelomaFirst studyNCT03318861 · 17 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study Gilead Sciences leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03318861Multiple Myeloma · United States1TerminatedDec 17, 201817

How it is read

Names in the registry

  • “Cyclophosphamide”, 74 entries
  • “cyclophosphamide”, 9 entries
  • “Cyclophosphamide,Fludarabine”, 4 entries
  • “Cytoxan”, 3 entries
  • “CHOP”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.